PATENT CLAIM ANALYSIS

Application Number: 16366818
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-07
Patent Classification: ["514", "108000"]

Abstract:
Oral dosage forms of osteoclast inhibitors, such as neridronic acid, in an acid or a salt form, can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.

Claim (Index 1):
A method of treating pain in a human being suffering from complex regional pain syndrome (CRPS) comprising administering neridronic acid in an acid form or a salt form to the human being suffering from CRPS and insomnia, with the result that 12 weeks from the first day that the neridronic acid is administered to the human being, the human being has an average pain intensity score, according to the 0-10 numerical rating scale (NRS), that is at least about 10% lower than it was at baseline.

Metadata:
- Claim Count in Document: 74.0
- Percentile: 99.0
- Lexical Diversity: 1.3
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15820305', '15782480', '15703891', '15814745', '15710759']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7504932983036829
- 35 USC 102 Novelty (BERT): 0.5664872732044804
- Combined Prediction Score: 0.7320926957937627
- Mean Citation Score: 299.617522
- Max Citation Score: 314.9670700000001
- Similarity Product: 215.6615987328757

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test